Elias Zerhouni News
-
Sanofi and the French government presented conflicting views on plans for the future of the drugmaker’s research site in Toulouse, adding another wrinkle in the company’s reorganization attempts.
-
Sanofi, France’s biggest drugmaker, is advancing its overhaul of research and development, with the goal of becoming the industry leader in bringing new medicines to market, said Elias Zerhouni, the president of global R&D.
-
Sanofi, France’s biggest drugmaker, is considering options for a once-weekly GLP-1 diabetes treatment, Elias Zerhouni, Sanofi’s global research and development chief, said.
-
Few government programs seem as sacrosanct as funding for medical research. Despite continuing U.S. budget constraints, both Democrats and Republicans regularly pledge to increase funding for the National Institutes of Health and other government medical research.
-
Sanofi said profit may drop as much as 5 percent this year as generic competition to the Plavix blood thinner crimps sales and it spends to introduce new medicines. The stock fell the most in nine months.
-
Sanofi, France’s biggest drugmaker, told employees it will proceed with plans to end research operations in Toulouse, on the same day PSA Peugeot Citroen said it would shut its first car factory in the country in 20 years.
-
Sanofi-Aventis SA named Elias Zerhouni head of research and development, replacing Marc Cluzel , a further step in Chief Executive Officer Chris Viehbacher ’s reorganization of France’s biggest drugmaker.
-
An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc. lowered patients’ so-called bad cholesterol by as much as 72 percent on top of Lipitor in a company-funded study.
-
The following is a list of companies whose shares may have unusual price changes in Zurich. Stock symbols are in parentheses after company names. Share prices are from the last close.
-
The following is a list of companies whose stocks may have unusual changes in Paris. Symbols are in parentheses after company names and prices are from the last close.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page